SMi are proud to present the 14th Annual Advances and Progress in Drug Design Conference, convening in Central London, United Kingdom on Monday 16 and Tuesday 17 February 2015 at the Marriott Hotel, Regents Park.
The drug is most commonly an organic small molecule that activates or inhibits the function of a biomolecule such as a protein, which in turn results in a therapeutic benefit to the patient. Drug design involves the designing of small molecules that are complementary in shape and charge to the biomolecular target with which they interact and therefore will bind to it. Drug design, is the inventive process of finding new medications based on the knowledge of the biological target.
As science and technology is advancing, drug designing has moved from traditional methods to advanced methods like computer aided drug designing and computational techniques. This informative event will focus on the recent developments and growth drivers in drug design.
High profile scientists from pharma companies and biotech organisations will be speaking about structure based drug designing, fragment based drug designing, computer based drug designing, pharmacokinetics, polypharmacology and metabolism in drug designing.
- Andreas Bender – Lecturer for Molecular Informatics, University of Cambridge
- Ben Allen – Computational Research Scientist, e-Therapeutics plc
- Gary Tresadern – Principal Scientist-Computational Chemistry, Janssen Research & Development
- Gianni Chessari – Director, Computational Chemistry, Astex Pharmaceuticals
- Gregg Siegal – Chief Scientific Officer, ZoBio BV
- Hugo Gutierrez de Teran – Senior Researcher, Division of Computational and Systems Biology, Uppsala University
- Michael Overduin – Professor of Structural Biology, University of Birmingham
- Oliver Plettenburg – Head of Biosensors & Chemical Probes, Sanofi-Aventis
- Sudharsan Sridharan – Scientist, MedImmune Inc.
- Zara Sands – Principal Scientist, Medicinal Chemistry, UCB BioPharma
- Application of Computational Structural Biology Tools in Biotherapeutics Discovery
- Building a Robust Technology Pipeline for Robust Fragment Based Drug Discovery
- Compound Design and Analysis Using Integrated Chemical and Biological Information
- Creating Focused Mutant Libraries for Protein Engineering
- Fragment Based Design of Protein-Protein Interaction Antagonists
- High End GPCR Design: the Slippery Slope to Potency, Selectivity and Kinetics
- How Have Computational and Predictive Tools Matured for the Application of Drug Discovery?
- Identification of Drug Candidates Using Network Pharmacology Based Computational Modelling
- Nmr-Based Fragment Screening and Validation for Novel Kinase and Phosphate Targets
- Predicting Protein Structure, Ligand Binding And Receptor Selectivity on GPCRs
- Rational GPCR Drug Discovery?
- Structure Based Design of PDE2 Inhibitors
- Structure-Based Design of Kinase Inhibitors
- The Abc of Kinase Conformations – Interplay of Conformation, Sequence And Ligand Binding
- Using Chemical and Biological Information for Compound Selection and Prioritisation
- Using X-Ray Structures on the Design of MK2 Kinase Inhibitors
Who should attend?
SMi’s 14th annual Advances and Progress in Drug Design Conference will build on the success of our previous events and bring together a unique mix of senior executives from all over industry and academia and will be an unrivalled forum for problem-solving discussion and debate.
This event is unmissable for VPs, Directors, Heads, Senior Managers and Principal Scientists from the following departments:
- Cancer Research
- Clinical Development
- Computational Chemistry
- Computer-Aided Drug Design
- Drug Discovery & Design
- Medicinal Chemistry
- Molecular Imaging
- Molecular Interaction
- Neuroscience Chemistry
- Structural Biology
- Structure and Informatics
- Target Discovery
- Translational Sciences